Latest news with #GIP
The Irish Sun
2 days ago
- Health
- The Irish Sun
I was on RTE's OT but I've lost 27lbs in weeks with €235 jabs and still eat burgers and pizza, it's changed my life
FROM appearing on Operation Transformation at 27 stone to trying brutal low-calorie diets, Mark Fearon has struggled with his weight for the past 15 years. But the 6 Mark appeared on Operation Transformation 15 years ago 6 Mark is happier than ever since dropping the pounds 6 Mark can still enjoy pizza and a drink Mounjaro (tirzepatide) has been growing in popularity in Ireland over the last few months. By activating GIP and GLP-1 receptors, Mounjaro slows down the emptying of the stomach, making you feel fuller for longer and reducing appetite. And Mark, from Stepaside, told how while his weight has "crept" up over the years, he's starting to see real results with the drug. Now weighing 19 stone, 47-year-old told the Irish Sun: "Ever since then I have been trying to lose 10 stone and I have gotten the weight down but never the 10. "The weight kept creeping back and ever since then I decided I had to do something about it. "Weight loss is obviously one of the main side effects of Mounjaro, as I lost 27lbs in just six weeks. "I've lost weight quickly before but this is different, I'm actually eating loads of calories. "I am having around 2,500 calories a day so I am not starving myself." Mark, who appeared on hit He said: "When I tried to lose weight before, I would eat very few calories, but this resulted in me having very little energy. I went from 27 lbs in six weeks with Mounjaro after 15 years of trying to lose weight it has completely changed my life "So this time I am actually eating enough calories to keep active, so I am actually in the gym all the time. "For the first time losing weight, I am actually feeling great doing it, I'm not feeling deprived. "I'd eat well during the week and then at the weekends I'd love takeaways. "Pizza and burgers being the favourite but there isn't much I wouldn't enjoy eating. "It's amazing, but the urges for these foods are just gone being on Mounjaro. "Without Mounjaro I'd be saying, 'Well I had a burger so there's no point eating well for the rest of the day' and would throw in ice cream and chocolate. Now I eat without any urges of a binge. "In the past six weeks I have eaten out a few times where I had a pizza and a burger but the difference is that I had them and that satisfied me." Speaking about the side effects, he said: "I get heartburn a bit more but I just pop two Rennies and it's gone. "Obviously, there is the risk of stopping taking it and putting the weight back on but is that not the case with every single diet?" 'BIG DIFFERENCE' And Mark hit back at the haters calling it the "lazy way out" as he revealed he has so much energy that he does not even watch television anymore. He said: "I'm up at 5am every morning before work so I can go to the gym and this is while I'm losing serious amounts of weight. "The big difference with Mounjaro is I am still able to eat, but I eat what I need, no more, as the desire to overeat is gone. "I have so much energy now and it has made me so active that I don't even watch TV anymore, as when I sit down all I want to do is get up and be active." When asked on the financial aspects of the weight loss jab, Mark said he was "just swapping one thing he spent money on for another" in relation to takeaways, dinners and drinks. He said: "I'd spend easily €50 per week on takeaways, plus throw in tubs of Ben and Jerry's. "Mounjaro costs me €250 per month from the North. This includes the monthly consultation, the Mounjaro and the tracked delivery to my home. "The greatest thing about the price is that no matter the higher dosage you go on, the cost stays the same. "And that cost is easily what I spent on food I didn't need to eat and no longer do on Mounjaro." Mark said he has full support from his doctor, adding: "I do get my Mounjaro from the North but my GP is fully aware of it and is also very supportive of me being on it." SUPPORT SYSTEM Mark has been sharing his weight loss journey for more than 15 years on Facebook, Instagram and more recently on TikTok. He said: "I get a lot of private messages from people asking questions especially about Mounjaro. "Some people want to do it, but really do not want anyone to know." WHAT ARE THE SIDE EFFECTS OF WEIGHT LOSS JABS? Like any medication, weight loss jabs can have side effects. Common side effects of injections include: Nausea : This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts. Vomiting : Can occur, often in conjunction with nausea. Diarrhea : Some people experience gastrointestinal upset. Constipation : Some individuals may also experience constipation. Stomach pain or discomfort : Some people may experience abdominal pain or discomfort. Reduced appetite : This is often a desired effect for people using Ozempic for weight loss. Indigestion : Can cause a feeling of bloating or discomfort after eating. Pancreatitis : In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting. Kidney problems : There have been reports of kidney issues, including kidney failure, though this is uncommon. Thyroid tumors : There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic. Vision problems : Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic. Hypoglycemia (low blood sugar) : Especially if used with other medications like sulfonylureas or insulin. But Mark has no shame or secrecy when it comes to his journey and said his family have been "very supportive of him". He said: "I have been trying for 15 years to get my weight to a place I'd be happy with. "I set myself a target of losing 10 stone, then I've never accomplished it, I'm now 19st 13lbs and I've lost 27lbs in six weeks on Mounjaro. "I know I will get to my goal of that 10 stone down now with the help of Mounjaro. "My friends and family know how important that is to me, and they are very supportive of me being on Mounjaro." The latest weight loss drug was only approved for use in Ireland in early 2025, being licenced for use as a treatment for both type 2 diabetes and obesity. And Mark is not the only Irish person seeing big health changes since trying the fat jab. EATING 'ADDICTION' Irish mum Sandra Keogh spent hundreds of euros every month on Doritos as her The former weight loss consultant, 37, said she needed to urgently make a change but had already tried all of the usual routes. She said: "I felt unable to find the will to care what I was shoving in my mouth. "It was compounded by the fact that I knew what I should be doing I just felt useless. I had to try something else." But she had a light bulb moment one day after sitting down to watch a bit of reality TV. The "So after a while when I heard about availability here, I went and spoke to my doctor because I haven't had diabetes but I just needed something. "I knew what had to be done, but I didn't have the willpower or the motivation to do anything. "I started Ozempic in November 2023 after the doctor thought it was a great idea. "I was on it until February this year and when I heard Mounjaro was coming in, I was eager to swap because I had lost 33 pounds on Ozempic and I kind of had stalled. "When I heard that Mounjaro was going to be approved for weight loss here in Ireland, I thought, 'Right, I'm going to try and get it'. "I started taking it on the 25th of March and I began losing weight again." 6 Mounjaro was Mark's last resort to help him lose the weight 6 He documents his journey on his TikTok account 6 Mark is also working hard at the gym
Yahoo
13-06-2025
- Business
- Yahoo
Green Impact Partners Announces Amendment to Its Corporate Credit Facility and Closes Term Loan
Calgary, Alberta--(Newsfile Corp. - June 12, 2025) - Green Impact Partners Inc. (TSXV: GIP) ("GIP" or the "Company") announces that the Company has executed an amendment to its corporate credit facility (the "Facility") to provide a waiver of certain events of default under the Facility until June 30, 2025. With this waiver, the Facility lender no longer has the right to demand repayment and/or realize on the security until June 30, 2025. In addition to the waiver, certain covenant and reporting requirements under the Facility have been amended. GIP also announces funding of a $2.0 million loan (the "Loan") with a company controlled by the Company's Chief Executive Officer ("CEO"). On closing of the Loan, the CEO funded the first $1.5 million with $0.5 million available for future funding subject to certain customary conditions. The details of the term loan were previously announced on May 21, 2025, and the funds will be used for working capital purposes. With respect to the sale of the Company's water and recycling assets, as previously announced, GIP expects the transaction to close on or before June 30, 2025. Completion of the transaction remains subject to the satisfaction or waiver of certain customary closing conditions, including the approval of the TSX Venture Exchange ("TSXV"). GIP has also posted an updated investor relations presentation to its website. Please visit The Loan is a related party transaction under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Loan transaction is exempt from the requirement for a formal valuation and minority approval in accordance with, respectively, sections 5.5(b) and 5.7(a) of MI 61-101, as the Company is listed on the TSXV and the fair market value of the Loan transaction does not exceed 25% of the Company's market capitalization. About Green Impact Partners Inc. Green Impact Partners Inc. is forging a path towards a sustainable future by turning waste into energy. With a focus on renewable natural gas (RNG) and bioenergy projects, our mission is to acquire, develop, construct, and operate facilities that not only produce energy but also play an important role in waste reduction and lowering emissions. Our comprehensive approach spans the entire project life cycle, from idea generation through construction to ongoing operations. In addition to our RNG and bioenergy projects, GIP maintains a current portfolio of water and solids treatment and recycling facilities in Canada, alongside a solids recycling business in the United States. Traded on the TSX Venture Exchange under the symbol 'GIP', the Company invites you to join us in our journey. For more information about the Company, please visit Investor & Analyst Inquiries: Nikolaus KieferChief Investment Officer(236) 476-3445investors@ Media Inquiries: media@ Cautionary Statements This news release contains forward-looking statements and/or forward-looking information (collectively, "forward-looking statements") within the meaning of applicable securities laws. When used in this release, such words as "would", "will", "anticipates", believes", "estimates", "explores" "expects" and similar expressions, as they relate to GIP, or its management, are intended to identify such forward-looking statements. Such forward-looking statements reflect the current views of GIP with respect to future events, and are subject to certain risks, uncertainties and assumptions. Many factors could cause GIP's actual results, performance or achievements to be materially different from any expected future results, performance or achievement that may be expressed or implied by such forward-looking statements. Certain information and statements contained in this news release constitute forward-looking statements, which reflects the Company's current expectations regarding future events, including but not limited: the anticipated closing of the sale of the Company's water, waste treatment, and recycling facilities; securing regulatory and exchange approvals; anticipated cash to the Company at closing. Forward-looking statements are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: the high degree of uncertainties inherent to feasibility and economic studies which are based to a significant extent on various assumptions; variations in commodity prices and exchange rate fluctuations; variations in cost of supplies and labour; lack of availability of qualified personnel; receipt of necessary approvals; availability of financing for project development; uncertainties and risks with respect to developing RNG projects; general business, economic, competitive, political and social uncertainties; assurance that the final terms will align with those initially agreed upon or that the transaction will proceed as anticipated; timeline of construction and ultimate completion of the Future Energy Park project; change in demand for clean energy to be offered by the Company; obtaining required approvals of regulatory authorities; ability to access sufficient capital from internal and external sources. For a more fulsome list of risk factors please see the Company's December 31, 2024, year-end Management Discussion and Analysis ("MD&A"), and AIF available of SEDAR+ at Management of the Company has included the above summary of assumptions and risks related to forward-looking statements provided in this release to provide shareholders with a more complete perspective on the Company's current and future operations and such information may not be appropriate for other purposes. The Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements included in this news release should not be read as guarantees of future performance or results. Accordingly, readers should not place undue reliance on forward-looking statements. The Company does not undertake to update any forward-looking statements, except in accordance with applicable securities laws. This news release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. To view the source version of this press release, please visit
Fashion Value Chain
10-06-2025
- Business
- Fashion Value Chain
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Dr. Ramkesh Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages Indias CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information
Globe and Mail
10-06-2025
- Business
- Globe and Mail
GFL in talks to sell stake in infrastructure arm, source says
Canadian waste management giant GFL Environmental Ltd. GFL-T is in talks to sell a stake in its infrastructure arm, GIP, in a deal that would value GIP's equity around $3.3-billion, according to someone familiar with the situation. GIP stands for Green Infrastructure Partners and was spun out of the waste management company in early 2022. GIP's services include demolition, excavation and remediation, and the company bulked up by purchasing Coco Paving, a family business run by siblings Jenny and Rock-Anthony Coco that predominately operates in Ontario. GIP was created with financing from private equity firm HPS Investment Partners, which took a 47 per cent stake, while GFL kept 45 per cent and GFL co-founder Patrick Dovigi owned eight per cent. Mr. Dovigi has long talked about wanted to monetize the business, potentially through an initial public offering, but GIP faced headwinds in recent years, partly owing to cost inflation on projects. GIP has also replaced a number of executives, including its CEO. Instead of going public, GIP is now in talks to sell a stake in the business, though the expect percentage to be sold remains unclear. A deal would allow existing owners to cash out some of their holdings, and would also provide some capital for growth, according to the source. The Globe and Mail is not naming the source because they were not authorized to speak publicly about the transaction. After adding in $1.3-billion in debt, the deal would give GIP an enterprise value around $4.5-billion, according to the source. There are currently six private capital firms in the bidding process, and the deal is expected to close mid-summer, although talks could fall apart if market conditions deteriorate. More to come
NDTV
09-06-2025
- Health
- NDTV
Mounjaro Side Effects: From Nausea To Kidney Problems, Here Are All The Possible Harmful Effects
Quick Read Summary is AI generated, newsroom reviewed. Mounjaro (tirzepatide) is a weekly injectable drug for type-2 diabetes that aids weight loss by regulating appetite. Common side effects include nausea, diarrhea, and abdominal pain. Consult a doctor before use and monitor for potential interactions and side e Mounjaro is a brand name for tirzepatide, a prescription drug primarily used to manage type-2 diabetes. This once-weekly injectable drug helps maintain healthy blood sugar levels by mimicking two important hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) that regulate insulin secretion and appetite. Recently, it has gained attention in the realm of weight management. Mounjaro aids in weight loss by promoting feelings of fullness and reducing hunger, which contributes to a lower calorie intake. It is used widely by individuals who are overweight or obese, even those without diabetes, to shed weight more easily. While there are benefits to using Mounjaro, it can also cause side effects. Below are some of the most common side effects reported: Side effects of Mounjaro As with any medication, Mounjaro can cause side effects. Some of the most common side effects reported include: 1. Nausea This is the most frequently reported side effect and often decreases over time. Mounjaro slows down the emptying of the stomach which can cause nausea. 2. Diarrhea Some individuals may experience gastrointestinal issues such as diarrhea, which can subside as the body adjusts. 3. Vomiting Similar to nausea, vomiting can occur, especially when starting the medication. 4. Constipation Due to changes in appetite and reduced intake of calories, Mounjaro can cause constipation. Adding more dietary fibre to the diet may help elevate this issue. 5. Abdominal pain Discomfort in the stomach area is another potential side effect. These symptoms often subside as the body gets used to it. Serious side effects, although rare, can include pancreatitis, gallbladder issues, kidney problems, allergic reactions and severe gastrointestinal issues. It is crucial to seek medical attention immediately if you experience severe abdominal pain, changes in urination, or any signs of an allergic reaction. Safety tips to follow 1. Consult a healthcare professional Mounjaro is a prescription drug. Always speak to your doctor before starting Mounjaro. They can assess your medical history and determine if it's a suitable option for you. 2. Check blood sugar levels regularly If you have diabetes, regularly checking your blood sugar levels is essential, especially when starting Mounjaro. 3. Start with low doses Begin with a low dose to mitigate side effects and allow your body to adjust gradually. However, it is best to administer the dose prescribed by your doctor. 4. Follow a balanced diet While Mounjaro can aid in weight loss, pairing it with a healthy, balanced diet can help keep digestion healthy. 5. Stay hydrated Due to potential gastrointestinal effects, ensure you drink plenty of fluids to stay hydrated. 6. Be aware of potential interactions Check with your doctor if you are currently taking any medication to avoid any potential interactions. Keep track of any side effects you experience and attend regular check-ups with your doctor. It is advisable to undergo regular kidney function tests, liver function panels, and monitor for any abdominal symptoms while using this medication. Mounjaro is generally considered safe for use under medical supervision, especially for individuals who are overweight or obese. While it offers substantial benefits, understanding potential side effects and adhering to safety measures is crucial.
